Zobrazeno 1 - 2
of 2
pro vyhledávání: '"John Bomalaski, MD"'
Autor:
Teresa A. Szyszko, MD, FRCR, Joel T. Dunn, PhD, Melissa M. Phillips, MD, PhD, John Bomalaski, MD, Michael T. Sheaff, MD, Steve Ellis, MD, Lucy Pike, PhD, Vicky Goh, MD, FRCR, Gary J.R. Cook, MD, FRCR, Peter W. Szlosarek, MD, PhD, FRCP
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100382- (2022)
Introduction: Pegargiminase (ADI-PEG 20I) degrades arginine in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma (MPM) and NSCLC. Imaging with proliferation biomarker 3'-deoxy-3'-[18F] fluorothymidine (18F-FLT) pos
Externí odkaz:
https://doaj.org/article/24b63e146e99419791c4c911d1a9c802
Autor:
Peter W. Szlosarek, MD, PhD, Melissa M. Phillips, MD, PhD, Iuliia Pavlyk, PhD, Jeremy Steele, MD, Jonathan Shamash, MD, James Spicer, MD, PhD, Sanjeev Kumar, MD, Simon Pacey, MD, PhD, Xiaoxing Feng, PhD, Amanda Johnston, PhD, John Bomalaski, MD, Graeme Moir, MD, Kelvin Lau, MD, Stephen Ellis, MD, Michael Sheaff, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100093- (2020)
Introduction: Pegargiminase (ADI-PEG 20; ADI) degrades arginine and potentiates pemetrexed (Pem) cytotoxicity in argininosuccinate synthetase 1 (ASS1)–deficient malignant pleural mesothelioma (MPM). We conducted a phase 1 dose-expansion study at th
Externí odkaz:
https://doaj.org/article/b61eaabe82a64253a698a897597a8afc